STOCK TITAN

Sage Therapeutics, Inc. - $SAGE STOCK NEWS

Welcome to our dedicated page for Sage Therapeutics news (Ticker: $SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutics stock.

Sage Therapeutics, Inc. (SAGE) is a pioneering, neuroscience-focused biopharmaceutical company dedicated to developing medicines for life-threatening and rare central nervous system (CNS) disorders. Founded in 2010, Sage Therapeutics aims to improve the lives of patients suffering from various CNS diseases through breakthrough scientific research, robust clinical trials, and strong partnerships.

The company is primarily engaged in three key focus areas: depression, neurology, and neuropsychiatry. Sage's lead compound, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE), marking the first of many potential seizure medicines in its extensive pipeline. Another notable treatment, Zurzuvae, targets postpartum depression (PPD) in adults, while Zulresso is a CIV injection designed for individuals aged 15 and older dealing with PPD.

In addition to these approved treatments, the company’s pipeline features several promising compounds, including SAGE-324 and Dalzanemdor (SAGE-718), which are currently under various stages of development. Sage Therapeutics leverages two critical CNS receptor systems, GABA and NMDA, to develop its innovative treatments.

Sage’s commitment to compelling science and robust clinical foundations is fortified by its world-class team of founders, advisors, investors, scientists, and managers. The company prides itself on its collaborative efforts, fostering strategic partnerships to enhance its research and development capabilities. These efforts underscore Sage Therapeutics' mission to discover, develop, and deliver significant new medicines to address unmet medical needs in the CNS space.

Rhea-AI Summary

Sage Therapeutics announced topline results from its Phase 2 SURVEYOR Study for Huntington's Disease (HD). The study met its primary endpoint, highlighting a significant cognitive difference between healthy participants and those with HD, as measured by the HD-Cognitive Assessment Battery (HD-CAB).

Dalzanemdor (SAGE-718) was generally well-tolerated, with no new safety signals observed. The study involved 40 participants with HD and 29 healthy controls. While the study wasn't designed to show a significant difference between dalzanemdor and placebo, a small numerical improvement was noted in cognition for those on dalzanemdor.

Sage plans to apply these findings to future research and expects to report further data from the dalzanemdor program in late 2024, including studies on Alzheimer's Disease and additional HD cognitive impairment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
-
Rhea-AI Summary

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company focused on brain health, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will include a fireside chat scheduled for June 12, 2024, at 2:00 p.m. ET in Miami, FL. Interested parties can view a live webcast of the presentation on Sage's Investor page. A replay will be available for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
conferences
-
Rhea-AI Summary

Sage Therapeutics, a biopharmaceutical company, will participate in investor conferences in May, including the 2024 RBCCM Global Healthcare Conference and BofA Securities 2024 Health Care Conference. The Company aims to create a world with better brain health. Live webcasts and replays of the presentations will be available on Sage's Investor page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
conferences
Rhea-AI Summary
Sage Therapeutics reported $6.2 million in collaboration revenue for ZURZUVAE in Q1 2024, with 700+ prescriptions shipped. Payor coverage for ZURZUVAE expanded, but Phase 2 PRECEDENT Study did not meet primary endpoint. Cash position stood at $717 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
-
Rhea-AI Summary
Sage Therapeutics announced topline results from the Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the treatment of mild cognitive impairment in Parkinson’s Disease. The study did not show statistically significant differences versus placebo on the primary endpoint. Dalzanemdor was well-tolerated with no new safety signals observed. Topline data from Phase 2 studies in Huntington’s disease and Alzheimer’s disease are expected later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.58%
Tags
-
Rhea-AI Summary
Sage Therapeutics, Inc. (SAGE) will host a live webcast to review first quarter 2024 financial results and discuss recent business updates on April 25, 2024. The webcast can be accessed on the Investor page of Sage's website. A replay will be available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences earnings
Rhea-AI Summary
Sage Therapeutics (SAGE) will present at investor conferences in March, including TD Cowen 44th Annual Health Care Conference and Stifel 2024 Virtual CNS Days. The events will feature fireside chats with live webcasts accessible on Sage's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
conferences
-
Rhea-AI Summary
Sage Therapeutics reports encouraging early launch results for ZURZUVAE, the first oral treatment for postpartum depression, achieving $0.8 million in collaboration revenue. The company anticipates significant value creation in 2024 with multiple data read-outs. Financially, Sage ended 2023 with $753 million in cash, cash equivalents, and securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.86%
Tags
-
Rhea-AI Summary
Sage Therapeutics, Inc. (NASDAQ: SAGE) will host a live webcast to review fourth quarter and full year 2023 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences earnings
Rhea-AI Summary
Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the upcoming launch of ZURZUVAE™ (zuranolone), the first oral treatment for adults with postpartum depression (PPD) in December 2023. The company also highlighted progress on clinical pipeline with topline data expected from multiple ongoing Phase 2 trials across 2024, positioning itself for a catalyst-rich year supported by a strong financial foundation and focused execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.91%
Tags
none

FAQ

What is Sage Therapeutics, Inc. focused on?

Sage Therapeutics, Inc. focuses on developing medicines for life-threatening and rare central nervous system (CNS) disorders.

What are the key focus areas of Sage Therapeutics?

The key focus areas of Sage Therapeutics are depression, neurology, and neuropsychiatry.

What are some of the main products of Sage Therapeutics?

Some main products include Zurzuvae for postpartum depression and Zulresso, a CIV injection for postpartum depression in individuals aged 15 and older.

What is SAGE-547?

SAGE-547 is Sage Therapeutics' lead compound, currently in clinical development for super-refractory status epilepticus (SRSE).

What are the current projects in Sage Therapeutics' pipeline?

Current projects in Sage Therapeutics' pipeline include SAGE-324 and Dalzanemdor (SAGE-718), among others.

What receptor systems does Sage Therapeutics target?

Sage Therapeutics targets the GABA and NMDA receptor systems to develop its treatments.

When was Sage Therapeutics founded?

Sage Therapeutics was founded in 2010.

Who makes up the team at Sage Therapeutics?

The team at Sage Therapeutics includes founders, advisors, investors, scientists, and managers.

What is the mission of Sage Therapeutics?

The mission of Sage Therapeutics is to improve the lives of patients with CNS diseases by discovering, developing, and delivering important new medicines.

How does Sage Therapeutics enhance its research and development capabilities?

Sage Therapeutics enhances its research and development capabilities through strategic partnerships and collaborative efforts with its world-class team.

Sage Therapeutics, Inc.

Nasdaq:SAGE

SAGE Rankings

SAGE Stock Data

646.96M
47.55M
12.56%
95.55%
14.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE